Drugs / GamCoviMab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05729360 | Mar → Dec 2023 | COVID-19 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GamCoviMab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05729360 ↗ |